AAM Welcomes Potential USMCA Revision
Rumors That US Negotiators May Scale Back Intellectual Property Provisions
The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.
